Week Ending Friday, November 20, 2026
U.S. stocks finished a turbulent week with a sharp Friday selloff as concerns about artificial intelligence valuations, infrastructure financing and policy uncertainty overwhelmed an improvement in consumer confidence. The Nasdaq Composite dropped 5.28% in the final…
Positive Phase 3 leukemia results, progress in Parkinson’s drug delivery and a $2.2 billion acquisition agreement put clinical differentiation back at the center of the healthcare investment case.
Biotechnology’s most persuasive sales pitch is not a larger addressable-market slide. It is evidence…
A Precision-Oncology Bet With Room to Grow
Eli Lilly and Company (NYSE: LLY) is adding another potential growth engine to a business already well acquainted with acceleration. On November 16, Calytrix Bio announced a definitive agreement to be acquired by Lilly in…
A 68% Reduction in Recurrence Risk Sharpens the Growth Story
CG Oncology (NASDAQ: CGON) has delivered the kind of late-stage cancer result that can move a biotechnology company from promising science toward a more substantial commercial proposition. On November 16, the company…
NYSE trading floor with screens showing stocks sliding as rising U.S. Treasury yields and Walmart (WMT) earnings pressure risk assets on August 20, 2026.
SER-252 Advances as the Bullish Case Moves From Platform Promise to Clinical Execution
For a small biotechnology company, progress is best measured in patients dosed, safety reviews completed and the quality of the next clinical question. By those measures, Serina Therapeutics (NYSE American:…
A New Nasdaq Arrival With More Than a New Name
Biotechnology companies often arrive on Wall Street with an ambitious presentation and a conspicuously modest bank account. Mentari Therapeutics (Nasdaq: MTRI) has chosen a more substantial entrance. The Waltham, Massachusetts-based migraine-drug developer…
Serina's SER-252 Puts a Practical Innovation at the Center of the Story
Biotechnology often commands attention by promising an entirely new molecule. Serina Therapeutics (NYSE American: SER) is pursuing a different proposition: take an established therapeutic agent, improve how it reaches the patient and…
A Funded Biotech With a Date Worth Watching
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) is approaching a consequential clinical milestone with something that makes the occasion considerably more interesting: enough financial breathing room to focus on the science. The company’s November…
Healthcare’s most compelling growth stories often begin with an unglamorous proposition: make an existing problem less difficult to manage. For INOVIO Pharmaceuticals (NASDAQ: INO), that means a newly approved immunotherapy intended to reduce repeated surgeries. For IDEXX Laboratories (NASDAQ: IDXX), it means…
